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Strategic aims for improving the regulatory assessment of 
Developmental Neurotoxicity (DNT) using non-animal methods 
Anna Price, Francesca Pistollato, Sharon Munn, Stephanie Bopp and Andrew Worth 
Directorate General Joint Research Centre, Directorate F – Health, Consumers and Reference 
Materials, Chemical Safety and Alternative Methods Unit, European Union Reference Laboratory 
for Alternatives to Animal Testing (EURL ECVAM) 
Summary 
Currently, the identification of chemicals that have the potential to induce developmental 
neurotoxicity (DNT) is based on animal testing, since there are no regulatory accepted 
alternative methods for this purpose. Since at the regulatory level, systematic testing of 
DNT is not a standard requirement within the EU legislation of chemical safety 
assessment, DNT testing is only performed in higher tiered tests triggered based on 
structure activity relationships or evidence of neurotoxicity in systemic adult studies. 
However, these triggers are rarely used and in addition do not always serve as reliable 
indicators of DNT as they are observed in an adult rodent animal. Consequently, to date 
only a limited amount of chemicals (Grandjean and Landrigan, 2006; Smirnova et al., 
2014), mainly pesticides (Bjørling-Poulsen et al., 2008) have been tested under US EPA 
(OPPTS 870.630) or OECD DNT TG 426. Therefore, there is the pressing need for 
developing alternative methodologies that can more rapidly and cost-effectively screen 
large numbers of chemicals for their potential to cause DNT.  
In this report we propose that in vitro studies could contribute to the identification of 
potential triggers for DNT evaluation since existing cellular models permit the evaluation 
of a chemical impact on key neurodevelopmental processes, mimicking different 
windows of human brain development, especially if human models derived from induced 
pluripotent stem cells are applied. Furthermore, the battery of currently available DNT 
alternative test methods anchored to critical neurodevelopmental processes and key 
events identified in DNT Adverse Outcome Pathways (AOPs) could be applied to generate 
in vitro data useful for various regulatory purposes. Incorporation of in vitro mechanistic 
information would increase scientific confidence in decision making, by decreasing 
uncertainty and leading to refinement of chemical grouping according to biological 
activity. We suggest development of Integrated Approaches to Testing and Assessment 
(IATA) based on key neurodevelopmental processes and existing AOPs relevant to DNT 
(Bal-Price and Meek, 2017b) as a tool for not only speeding up chemical screening, but 
also providing mechanistic data in support of hazard assessment and in the evaluation of 
chemical mixtures. Such mechanistically informed IATA for DNT evaluation could be 
developed integrating various sources of information (e.g., non-testing methods, in vitro 
approaches, as well as in vivo animal and human data), contributing to screening for 
prioritization, hazard identification and characterization, and possibly safety assessment 
of chemicals, speeding up the evaluation of thousands of compounds present in 
industrial, agricultural and consumer products that lack safety data on DNT potential. It 
is planned that the data and knowledge generated from such testing will be fed into the 
development of an OECD guidance document on alternative approaches to DNT testing. 
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1. Introduction 
 
The developing nervous system is known to be more vulnerable to chemical exposure 
compared with the adult nervous system. The higher vulnerability of the developing 
brain results from the complex processes specific to development such as the 
commitment and differentiation of the neuronal progenitor cells followed by glial and 
neuronal cell proliferation, migration, differentiation into various neuronal and glial 
subtypes, synaptogenesis, pruning, myelination, networking and terminal functional 
neuronal and glial maturation (Rice and Barone 2000; Hogberg et al., 2009 and 2010; 
Stiles and Jernigan, 2010; Yang et al., 2014; Krug et al., 2013). A challenge in 
evaluation of developmental neurotoxicity (DNT) induced by a chemical is that the 
neurodevelopmental outcome depends not only on the kind of exposure (dose, duration) 
but also on the developmental stage of the brain at the time of exposure (Rice and 
Barone, 2000). Additionally, the immature blood brain barrier (BBB) is not completely 
formed thus facilitating the entrance of a chemical into the foetal/neonatal brain 
(Adinolfi, 1985).  
 
Currently, at the regulatory level, there is a recognized need for neurotoxicity evaluation 
(Bal-Price et al., 2012; 2015b), however systematic testing for DNT is not a mandatory 
requirement in the European Union for pesticides, biocides, pharmaceuticals or industrial 
chemicals. DNT testing is performed only as higher tiered tests that are triggered based 
on structure activity relationships or evidence of neurotoxicity in standard in vivo tests in 
adult animals, (Makris et al., 2009; Bal-Price et al., 2010 and 2012) either after acute 
exposure (OECD TGs 402, 403, 420, 423, 436 and 425), or repeated dose toxicity, sub-
chronic (OECD TG 407 and 408) or chronic exposure (OECD TG 452). Additionally, DNT 
studies can also be triggered when data from extended one–generation reproductive 
toxicity study (TG 443) indicate a possible concern of neurotoxicity (Bal-Price et al., 
2015b; ECETOC Document No 45). 
 
At the same time, for regulatory purposes the identification of chemicals with neurotoxic 
potential is entirely based on the use of in vivo animal tests since there are no officially 
accepted alternative methods for this purpose. Two regulatory guidelines for rodent in 
vivo test methods used for DNT evaluation (OECD DNT TG 426 and TG443: Extended 
one-generation reproductive toxicity study) are based on neurobehavioral evaluation of 
cognitive, sensory and motor functions accompanied by morphometric and 
histopathological studies. Additional testing, specifically of offspring that have been 
exposed in utero and during early lactation, includes also evaluation of sexual 
maturation, behavioural ontogeny and learning and memory (OECD DNT TG 426). 
However, this test is not accompanied by detailed guidance on its use, leaving large 
flexibility in the study design and in the interpretation of the results. 
 
These in vivo based guidelines are very resource intensive in terms of animals, time and 
overall cost (Rovida and Hartung 2009; Tsuji and Crofton 2012) and have been used 
only for a limited number of pesticides and industrial chemicals. Therefore there is only a 
small amount of DNT data available. Indeed DNT testing has been performed for less 
than 200 chemicals globally (Grandjean and Landrigan, 2006; Evans et al., 2016; 
Fritsche et al., 2017) mostly pesticides (Bjørling-Poulsen et al., 2008) and only a few of 
these studies contributed to risk assessment (Smirnova et al., 2014). Although the 
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majority of risk assessments can be considered protective for positive in vivo DNT 
effects, according to the authors animal DNT testing is not sufficient for covering hazards 
associated with DNT as animal DNT studies do not always identify human DNT toxicants 
(Aschner et al., 2017). This could be due to different pharmacokinetics in different 
species, including metabolic activity or placental transfer in animals compared to 
humans.  
These issues highlight the pressing need for developing alternative methodologies that 
can more rapidly and cost-effectively screen large numbers of chemicals for their 
potential to cause DNT. 
 
Decades of in vitro work using rodent and human neuronal models have delivered a 
range of reliable in vitro assays that currently permit quantitative evaluation (via 
concentration-response relationships) of the impact of a compound on key 
developmental processes and pathways critical for brain development. For instance, 
human neural stem cells can be used to assess several DNT-related endpoints, such as 
commitment and proliferation, apoptosis, cell migration, neuronal and glial 
differentiation, neurite outgrowth, myelination, axonal and dendritic elongation, synapse 
formation, synapse pruning, neurotransmitter receptor profiling, development of 
neuronal connectivity, spontaneous electrical activity, etc. (Fritsche et al., 2015; Coecke 
et al., 2007). Some of these assays are already at the High Throughput Screening (HTS) 
level, permitting a quantitative evaluation using a range of different in vitro cell models, 
including human induced pluripotent stem cell (hiPSC)-derived neuronal cultures. For 
instance, high-content analysis were performed by the U.S. EPA for neurite outgrowth 
(testing approximately 300 chemicals) (Mundy et al., 2010), including human iPSC-
derived neurons (80 chemicals) (Ryan et al., 2016; Druwe et al., 2016), neural 
proliferation (Breier et al., 2008; Mundy et al., 2010) and synaptogenesis (Harrill et al., 
2011). Biomarkers of neuronal and glial cell differentiation processes have been also 
identified using primary rodent cultures and human neural stem cells (Kuegler et al., 
2010) based on gene (Hogberg et al., 2010, 2011) and protein expression (Mundy et al., 
2008) as well as metabolomics and proteomics analysis (Schultz et al., 2015) and 
measurements of neuronal electrical activity under the exposure to different classes of 
chemicals including pesticides (Vassallo et al., 2016; Brown et al., 2016).  
 
The data produced from such in vitro DNT studies could be used to support chemical 
screening and prioritization, as well as hazard and risk assessment by delivering 
information on mechanisms of toxicity (mode of action), including interspecies 
differences.  
 
In this report, it is proposed to use the data derived from in vitro DNT studies within the 
context of Integrated Approaches to Testing and Assessment (IATA), for the following 
regulatory needs: 
 
 Providing supplementary mechanistic information on chemically-induced DNT to 
support their hazard assessment 
 Providing mechanistic data derived from alternative methods to support grouping 
and assessment of combined exposures to multiple chemicals (mixture risk 
assessment; MRA) with potential to induce DNT 
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 Providing supplementary information supporting triggering criteria for DNT testing  
 
 Introducing in vitro screening approaches to prioritize chemicals for further in 
vivo testing according to DNT TG 426 
 
To achieve these aims multiple sources of information need to be combined within IATA 
including data obtained from DNT in vitro assays, in silico modelling (such as QSARs) 
and read across as well as data obtained from non-mammalian species (for instance 
zebrafish model). At the same time the existing methods should be further optimized to 
be amenable for High Throughput Screening (HTS) and missing methods should be 
developed to expand the current set of available assays to ensure that critical key 
neurodevelopmental pathways and processes specific for DNT can be assessed using 
alternative approaches. 
 
2. Key considerations on IATA development for DNT 
 
A framework for the development of mechanistically-informed IATA for identification of 
chemicals with DNT potential should be based on various sources of information (non-
testing methods, in vitro approaches, in vivo animal and human data), delivering data 
for different regulatory purposes. The increasing availability of Adverse Outcome 
Pathways (AOPs) will facilitate use of mechanistic knowledge (including that coming from 
in vitro studies) in DNT regulatory decision making processes (OECD GD 260, 2016). 
 
Since an IATA should be customised for the specific regulatory need, the proposed IATA 
framework for DNT should consider a set of in vitro test methods for generation of 
missing data that can be used in a flexible combination (fit-for-purpose), anchoring the 
assays against molecular initiating events (MIEs) and a selected set of key events (KEs) 
at the cellular or tissue level described in the existing DNT-relevant AOPs 
(https://aopwiki.org; Bal-Price et al., 2015a; Bal-Price  and Meek, 2017b) and those 
other putative AOPs identified in the literature. The assays that allow an evaluation of 
the key biological processes specific for brain development such as cell proliferation, 
migration, differentiation etc., may also be combined, where appropriate, with non-
mammalian models (e.g. zebrafish) suitable for behavioural observations, some of which 
are available at HTS level. The HTS methods and those assays that are easily adaptable 
to an HTS platform should be used as first choice permitting the screening of a large 
number of chemicals, over a wide range of concentrations, in a time and cost-efficient 
manner.  
 
Understanding the likelihood of the triggered events described in the AOPs as MIEs or 
KEs at lower levels of biological organisation (e.g. in vitro testing at the cellular level) or 
information from structure-activity relationships, can help to inform whether testing at 
higher levels of biological organisation (i.e., in vivo) is warranted 
(ENV/JM/MONO(2016)29). 
 
Mechanistic information on pathways of toxicity specific for DNT could guide a design of 
IATA, composed of fit-for-purpose tools, including in vitro assays that are consistent with 
in vivo human biology, permitting evaluation of KEs identified in the relevant AOPs. 
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However, currently, only a few DNT AOPs are available (Bal-Price and Meek, 2017b) and 
the development of a sufficient number of specific DNT AOPs will take time. Therefore, 
so as not to delay development and implementation of a testing strategy, it was 
suggested during the OECD/EFSA DNT workshop (October 2016) that 
neurodevelopmental processes, whether or not incorporated into existing AOPs, can also 
be utilized as KEs, and thus chemical testing across a potential testing battery could feed 
back to inform further AOP development in the future (Fritsche et al., 2017; EFSA 
Workshop Report, 2017). 
 
The preferential use of human in vitro models is advisable since it will decrease the need 
of cross-species extrapolation from animal-based findings. Data produced from IATA will 
require different levels of scientific confidence and different levels of acceptable 
uncertainty depending on the regulatory purpose. For instance in the case of screening 
and prioritization purposes a greater level of uncertainty could be tolerated in 
comparison to hazard identification or risk assessment where higher levels of reliability, 
certainty and validation will be required. 
 
The final IATA design should be fit-for-purpose. Depending on the purpose and 
substance / mixture to be evaluated, it may require a different combination of DNT in 
vitro assays used together with other alternative tools such as QSAR, in silico modelling 
and possibly non-mammalian models. Therefore, different IATA solutions may be 
possible depending on the chemical(s) under investigation and the regulatory purpose 
and context (e.g., refining of in vivo testing, chemical screening, prioritization, grouping, 
hazard characterization or risk assessment).  An in vitro battery of DNT tests supporting 
IATA development for different aims is discussed below. 
 
 
3. How data derived from in vitro DNT testing could 
contribute to regulatory decision-making 
3.1 Providing supplementary mechanistic information on 
chemically-induced DNT to support hazard assessment 
 
Problem formulation: Many different classes of pesticides are designed to target the 
nervous system of insect pests. Because of the similarity of neurochemical processes 
across taxa these compounds are likely to be neurotoxic to humans. This concern is of 
particular relevance to the developing human brain which, as mentioned above, is 
inherently much more vulnerable to a chemically-induced damage than the adult brain. 
Therefore, this class of regulated chemicals should be recognized as a priority for 
evaluating DNT potential. 
 
The EFSA Panel on Plant Protection Products and their Residues (PPR Panel) delivered a 
scientific opinion on the DNT potential of the neonicotinoid insecticides acetamiprid and 
imidacloprid (EFSA Scientific Opinion, 2013) recommending that "in vitro assays may be 
regarded as complementary to animal testing because they may provide better 
understanding of the cellular/molecular mechanisms involved in developmental 
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neurotoxicity. As such, in vitro tests could be incorporated into a DNT testing strategy to 
obtain mechanistic information or for purposes of screening/prioritisation."  
 
Following this recommendation and focussing on the aspect of obtaining further 
mechanistic support, incorporation of supplementary information delivered from DNT in 
vitro testing and other alternative approaches (e.g. QSARs, computational modelling, 
read across) would increase weight of evidence and scientific confidence, provided by 
DNT in vivo studies (where results may often be equivocal/open to different 
interpretation) with respect to whether or not a chemical has the capacity to cause DNT 
effects and if so, by what mechanisms. 
 
This can be achieved by using a battery of in vitro assays which permit evaluation of a 
range of key pathways and processes specific for brain development of humans at 
different developmental time points (exposure windows) using not only rodent but also  
human models, where possible, due to known interspecies differences (Fritsche et al., 
2015).  
 
The mechanistic information derived from the in vitro DNT assays could be used as a 
basis for biological groupings of chemicals according to the common mechanisms of 
toxicity or modes of action. Currently, some existing chemicals, including pesticides are 
already grouped according to their mode of action for instance pyrethroids (binding to 
voltage-gated sodium channels), rotenoids (inhibition of electron transfer from iron-
sulphur centres in complex I to ubiquinone), and nicotinoids (binding to nicotinic 
acetylcholine receptors (nAChRs) mimicking the action of acetylcholine by opening the 
ion channels which allow the entry of Na+ and Ca2+ into cells). This type of pesticide 
classification could be further refined based on in vitro mechanistic data. QSAR analysis 
would permit further grouping of the chemicals according to their structure as it has 
been done for instance for organochlorines, organophosphates or carbamates.  
 
To facilitate biological grouping of chemicals, data could be generated by investigating 
effects at the molecular and cellular level using in vitro assays anchored to the key 
events of the relevant DNT AOPs (Bal-Price at al., 2015a), preferably those amenable to 
HTS, permitting testing of a larger number of chemicals, at the concentrations relevant 
to human exposure. 
 
 
In vitro mechanistic studies will build knowledge on toxicity pathways involved in a 
chemically-induced impairment of brain-specific processes, supporting chemical, 
including pesticide, hazard assessment by increasing weight of evidence and thus 
reducing uncertainties in human health risk assessment. 
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3.2 Providing mechanistic data derived from alternative methods 
to support grouping and assessment of combined exposures to 
multiple chemicals (mixture risk assessment (MRA)) with 
potential to induce DNT 
 
Problem formulation: Humans (including children) are indisputably co-exposed to 
more than one chemical at a time. Chemicals causing similar effects and adverse 
outcomes can contribute to combined effects even when present individually at safe 
concentration levels. Grouping and assessment of chemicals in mixtures for specific 
effects such as DNT can be supported using mechanistic data from alternative methods 
in AOP-based IATA.  
 
 
Chemicals that are known to trigger specific DNT effects belong to different chemical 
types such as organic solvents or metals, or to different use categories such as 
pharmaceuticals, industrial chemicals, biocides or pesticides. Approximately 218 
chemicals are identified as neurotoxicants of which 27 are metals or inorganic 
compounds, 41 are organic solvents, 48 are other organic substances and 102 are 
pesticides (Grandjean and Landrigan, 2014). In the most recent studies by Maffini and 
Neltner (2015) more than 300 chemicals were identified as potential DNT chemicals. 
These compounds belong to various regulatory use categories related to food, such as 
pesticides, food contact materials and food additives including flavourings, colourings 
and preservatives. These examples illustrate that common, similar or related toxic 
effects triggered by various chemicals may be differently regulated according to their use 
category and that combined effects of these chemicals across different regulatory 
domains are not currently considered (Evans et al., 2016). At the same time it is well 
documented in the existing literature that "mixture effects" can be greater than effects 
triggered by the most potent single chemical in a mixture, and the mixture effects may 
be additive or in some cases even synergistic (Kortenkamp et al., 2009; 2012; Kienzler 
et al., 2016).  
MRA is very relevant to DNT evaluation as, for example, breast milk has been found to 
contain chemicals regulated as pesticides, along with those regulated as cosmetics 
(including UV filters, parabens, phthalates), together with persistent organic pollutants 
(POPs) including polychlorinated biphenyls (PCBs) (Schlumpf et al., 2010) confirming the 
co-exposure of infants simultaneously to multiple chemicals.  
 
In the development and evaluation of IATA for the risk assessment of groups of 
chemicals associated with DNT, relevant mixtures should be defined based on realistic 
co-exposures or based on commonalities in chemical structure, key events, or adverse 
outcomes, depending on the purpose of the risk assessment and the problem 
formulation defined at the outset. DNT in vitro testing will facilitate the grouping of 
chemicals based on identification of impacts on shared key neurodevelopmental 
processes. 
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3.3 Providing supplementary information supporting triggering 
criteria for DNT testing under different regulations  
  
Problem formulation: The existing criteria for triggering DNT testing are based on 
systemic in vivo studies (short or long term) in adult rodents. However, adult animals 
cannot mimic processes that are specific to the brain during development. The current 
triggers are thus likely to be in some cases too insensitive to be able to decide when 
such studies are required. Therefore, there is a need to define in a more informed 
manner the criteria that should trigger DNT testing based not only on in vivo 
observations but also including triggers from in vitro studies that permit evaluation of 
pathways and processes specific for brain at different developmental stages. 
 
Currently, developmental neurotoxicity evaluation is triggered under REACH, PPP and BP 
regulations based on the effects observed in the systemic studies where, e.g. under 
REACH, depending on the tonnage level, a 28-day and/or a 90-day repeated-dose 
toxicity study is performed (e.g. OECD TG 407, 408/EU B.7, B.26). In case of chemicals 
produced or imported with volumes of over10 t/y, a repeated dose 28-day oral toxicity 
testing (OECD TG 407/EU B.7) together with a screening study for 
reproductive/developmental toxicity (TG 421) is required or a combination of a repeated 
dose toxicity study with the reproductive/developmental toxicity screening study (OECD 
TG 422) is recommended. At volumes over 100 t/y a sub-chronic (90-day) toxicity study 
(OECD TG 408/EU B.26) is required which can be waived under certain circumstances. 
 
Testing for DNT effects is considered when the following triggers, viewed as predictive of 
possible neurotoxic activity, are met: 
 
(1)  structural and morphological brain abnormalities  
(2)  clear signs of behavioural or functional adverse effects  
(3)  structure-activity relationships (a compound similar in structure to a known 
       neurotoxic chemical) 
(4)  mode of action of a chemical that has been closely linked to neurotoxic  
      or developmental neurotoxic effects (e.g. cholinesterase inhibition or thyroid 
      effects)  
However, these triggers are not specific for brain development and furthermore they are 
mostly observed in adult animals that are not always a relevant model, at least for 
evaluation of certain processes and pathways that take place only during brain 
development. As mentioned before complexity and vulnerability of the developing brain 
is very different from adult (mature) brain. More reliable triggers for DNT studies can be 
observed when both a repeated dose toxicity study (TG 407) and a 
reproductive/developmental toxicity screening study following TG 422 or 421 are 
available.  
Therefore, it is proposed that also in vitro studies could contribute to the identification of 
potential triggers for DNT testing since cell culture models (human and in some cases 
rodent) permit to study a chemical impact on the specific, key developmental pathways 
and processes relevant to humans, applying different exposure scenarios focussed on 
different windows of brain development that cannot be studied in the adult brain. 
Including triggers based on in vitro DNT assays would increase the probability of flagging 
chemicals with potential to cause specifically DNT as it would be based on experiments 
designed for DNT evaluation, using animal or human neuronal models that mimic key 
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processes specific for brain development including cell proliferation, migration, neuronal 
and glial differentiation, synaptogenesis, neuronal network formation and function, etc. A 
similar approach could be applied to the evaluation of critical signalling pathways that 
are fundamental for brain development such as BDNF, ERK, CREB, RTK-P13K-AKT, 
mTOR, PLCg1, NCAM-FGFR, GDNF-RET, Wnt, Shh, Notch, TGFβ-BMP and others 
(OECD/EFSA Workshop Report, 2017). If these signalling pathways or key 
neurodevelopmental processes would be affected by a chemical at the concentrations 
relevant to possible human exposure such information could serve as a potential trigger 
for further follow up in vitro or if necessary in vivo DNT studies. This approach could be 
of a particular importance in the process of 'substance evaluation' under REACH in a first 
step relevant to the identification of a SVHC (Substance of Very High Concern). 
Incorporation of supplementary in vitro data to support triggering criteria for DNT testing 
would be in compliance with the REACH regulation which encourages use of in vitro 
approaches where possible. Use of such data could be introduced into ECHA guidance 
and may also be considered for inclusion in the REACH annexes on information 
requirements. 
 
 
3.4 Introduction of in vitro screening approach to prioritize 
chemicals for further in vivo testing according to DNT TG 426 
 
Problem formulation:  the current in vivo OECD TG 426 is very resource intensive in 
terms of animals, time and overall cost. It is therefore rarely used resulting in a small 
number of chemicals tested for their DNT potential. Hence, there is an urgent need to 
develop non-animal methods that will speed up the process of chemical screening to 
identify those chemicals with DNT potential. 
 
The EFSA PPR Panel delivered a scientific opinion on the DNT potential of the 
neonicotinoid insecticides acetamiprid and imidacloprid (EFSA Scientific Opinion, 2013). 
To evaluate the DNT potential of these insecticides the PPR Panel commented on the 
current OECD DNT TG 426 stating that "DNT guidelines are complex, time consuming, 
costly and not suitable for routine testing of high numbers of chemicals. Some concerns 
in terms of feasibility and animal welfare have been raised in the scientific literature. 
Although the protocol of the guidelines is well designed and covers a broad window of 
exposure, the critical phase for some effects might be missed and not all effects would 
be found. Furthermore, the interpretation of results is difficult because of knowledge 
gaps concerning normal brain development on the functional, structural and molecular 
levels, thus complicating risk assessment of compounds (Beronius et al., 2013). A 
number of issues related to the interpretation of DNT studies have been raised such as 
excessive variability that may mask treatment-related effects."  
 
Additional review of the performance of developmental neurotoxicity (DNT) testing 
following DNT test guideline 426 (TG 426) was performed by Makris et al., (2009) 
stating that the OECD DNT guideline represents the best available science for assessing 
the potential for DNT in human health risk assessment, and data generated with this 
protocol are relevant and reliable for the assessment of these endpoints. The 
reproducibility, reliability, and sensitivity of these methods have been demonstrated, 
using a wide variety of test substances, in accordance with OECD guidance on the 
validation and international acceptance of new or updated test methods for hazard 
 10 
 
characterization. Multiple independent, expert scientific peer reviews affirm these 
conclusions. 
However, another review of the performance of DNT evaluations (Claudio et al., 2000) 
according to the US EPA DNT guideline (OPPTS 870.6300 - a prototype of the OECD TG 
426) concluded that current regulatory practice does not adequately require the conduct 
of developmental neurotoxicity tests and is insufficient to determine with certainty that 
no harm will occur to exposed infants and children.  
 
Summing up, based on the existing reviews (EFSA Scientific Opinion, 2013; Claudio et 
al., 2000; Makris et al.,2009) of both US EPA (OPPTS 870.6300) and the OECD (426) 
DNT TGs, in addition to the fact that they are not always triggered appropriately within 
the current tiered system for testing, the current DNT TG presents a number of 
challenges and limitations: 
 
 It does not expose developing animals during all critical periods of vulnerability 
 It does not assess effects that may become evident later in life  
 It does not include methodology for consideration of different pharmacokinetics in 
different animals and humans, including metabolic activity or placental transfer in 
animals compared to humans 
 Methodology for assessment of neurobehavioral, neuropathological, and 
morphometry is highly variable, flexible and guidance is not provided on data 
interpretation (consequently it is difficult to compare data between studies) 
 Testing of neurochemical changes is limited  
 Required tests provide little mechanistic understanding of the underlying 
pathways involved 
 The recommended methods are low throughput, time-and resource-consuming 
 
Deficiencies in the testing methodology for developmental neurotoxicants represent a 
significant gap and increase the uncertainty in the establishment of safe levels of 
exposure to developing individuals. This highlights the urgent need for developing new 
methodologies that can more rapidly and cost-effectively screen large numbers of 
chemicals for their potential to cause DNT (Bal-Price et al., 2015b; Fritsche et al., 2017). 
 
Considering the current information requirements for DNT evaluation within the existing 
regulations in the EU it is clearly impossible at this time to replace animal testing with 
alternative in vitro methods. Therefore, the efforts should be directed towards the 
overall improvement of the current in vivo testing following TG 426 by incorporating in 
vitro methods as a first step in a tiered approach. Similar consensus has been reached 
by the participants of the recent OECD/EFSA DNT Workshops (Fritsche et al., 2017, Bal-
Price at al., 2017a) during which it was suggested that in vitro DNT assays are ready to 
be used for chemical screening and prioritisation. However, for other regulatory needs, 
such as replacement of animal testing or deriving health-based exposure limits, these 
assays require further standardization to reach higher scientific confidence.  
 
4. Conclusion 
 
This JRC report describes possible applications of in vitro approaches for developmental 
neurotoxicity evaluation for various regulatory purposes. 
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The EFSA PPR Panel, OECD and US EPA support the development of an integrated in 
vitro developmental neurotoxicity testing strategy complementary to the rodent in vivo 
methods (OECD TG 426, US EPA TG OPPTS 870.6300, TG 443) in order to refine and 
speed up the evaluation of a high number of chemicals for their DNT potential. The 
battery of methods should be composed of robust, reliable and standardized in vitro 
assays, relevant for the assessment of human toxicity to support tiered, cost-effective 
chemical screening, hazard identification and characterisation as well as risk assessment. 
Therefore IATA has been proposed as a practical solution to provide testing strategies 
composed of in vitro assays anchored to key events identified in the DNT AOPs and other 
key neurodevelopmental processes. In parallel, further development of AOPs relevant to 
DNT should take place as they will provide mechanistic information on the causal links 
between MIEs, KEs and AO of regulatory concern, providing the biological context for the 
in vitro assays anchored to AOP(s) key events and facilitating development of AOP-
informed IATA for various regulatory purposes.  
 
Currently, the main task is to establish performance standards and readiness criteria for 
evaluation of individual in vitro DNT assays which can be fed into the development of a 
guidance on building testing strategies (consisting of in vitro methods and alternative 
organisms like the zebrafish) (Bal-Price et al., 2017a). Such a testing strategy (e.g. DNT 
AOP-informed IATA) should be challenged with a range of chemicals across the full 
battery of in vitro test methods to support validation and build confidence. These efforts 
should eventually support the development of an OECD Guidance Document (GD) on 
available in vitro DNT test methods used alone or in combination within the context of an 
IATA addressing various regulatory needs based on the principle of 'fit-for-purpose'. A 
proposal for such an OECD Guidance Document has been recently included in the OECD 
work programme and will be developed in collaboration with EFSA, European (including 
EC JRC) and USA DNT experts.  
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